QC Kinetix (Charlotte)
- PRP Therapy
- Shockwave Therapy
- Acne Treatment
- Arthritis Treatment
- Red Light Therapy
Charlotte, NC
Stem Cell Therapy clinics in Charlotte
Charlotte supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Atrium Health and Novant Health, and stem cell practice in the area spans SouthPark, Myers Park, and Uptown. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. North Carolina regulates physician practice through the North Carolina Medical Board. There is no state-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. Duke and UNC anchor regional academic trial activity. The 6 Charlotte clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and North Carolina Medical Board licensure checks.
NeoGenix Stem Cell and Regenerative Therapies
- PRP Therapy
- Shockwave Therapy
- Arthritis Treatment
- Stem Cell Therapy
Advanced Sports & Spine
- PRP Therapy
- Shockwave Therapy
- Arthritis Treatment
- Stem Cell Therapy
MD Hyperbaric
- Hyperbaric Oxygen Therapy (HBOT)
- Multiple Sclerosis (MS) Treatment
- Lyme Disease Treatment
- Stem Cell Therapy
Regulatory context
A note on North Carolina's stem cell therapy rules.
North Carolina cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in North Carolina for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. The Research Triangle hosts substantial academic IND-based regenerative medicine research.
-
North Carolina Medical Practice Act, NC General Statutes Chapter 90, Article 1
Establishes physician licensure and discipline through the North Carolina Medical Board. -
North Carolina Pharmacy Practice Act, NC General Statutes Chapter 90, Article 4A
Regulates compounding pharmacies aligned with federal 503A and 503B standards. -
North Carolina Unfair and Deceptive Trade Practices Act, NC General Statutes Chapter 75
Empowers the Attorney General and private plaintiffs to pursue deceptive marketing claims with treble damages available.
The FDA has issued warning letters to North Carolina clinics offering stem cell and exosome therapies. The North Carolina Medical Board has disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. The North Carolina Attorney General has used the Unfair and Deceptive Trade Practices Act to pursue providers making unsupported clinical claims, and Chapter 75 enables private class actions with treble damages, which raises the financial risk for noncompliant providers. Federal warning letters apply nationally.